PRF Technologies Ltd. PRFX
At closeNov 4, 2026, 6:35 AM EST
Pre-market · Nov 4, 6:35 AM ET
- YTD
- -77.85%
- 1 year
- -86.46%
- Market cap
- 2.49M
- EPS (ttm)
- -4.09
- Shares out
- 874.86K
- Forward P/E
- -0.37
- YTD return
- -77.85%
- 1-year return
- -86.46%
- Volume
- 3.52M
- Avg volume
- 258.29K
- Open
- 0.7702
- Previous close
- 0.7503
- Day's range
- 0.7101 – 0.7772
- 52-week range
- 0.691 – 7.95
- Beta
- 0.56
- Earnings date
- Feb 29, 2024
2Y -1.5990 (-69.22%)
Key statistics
- Enterprise value
- 339.62K
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -4.93M
- Total cash
- 2.78M
- Total debt
- 59.00K
- Return on equity
- -716.67%
- Short % of float
- 9.08%
- 50-day average
- 1.84
- 200-day average
- 3.57
Analyst view
- Strong buy0
- Buy0
- Hold1
- Sell0
- Strong sell0
Next earnings
Feb 29, 2024
Expected Feb 29, 2024. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 15, 2024 | Jun 1, 2024 | 0.00 | -9.60 | — | — |
| May 15, 2024 | Mar 1, 2024 | 0.00 | -65.27 | — | — |
| Feb 29, 2024 | Dec 1, 2023 | 0.00 | — | — | — |
| Nov 15, 2023 | Sep 1, 2023 | 0.00 | 11.52 | — | — |
| May 15, 2023 | Mar 1, 2023 | 0.00 | -52.79 | — | — |
| Mar 16, 2023 | Dec 1, 2022 | 0.00 | -69.59 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 24, 2024 | Maxim Group | down | Buy | Hold |
| Jun 26, 2024 | Maxim Group | reit | Buy | Buy |
About PRF Technologies Ltd.
PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- Israel
- Website
- painreform.com
News
PRF Technologies Strikes Non-Binding Term Sheet With Dotz Nano To Expand Dotz's Footprint In AI-Driven Energy Optimization Market; Dotz Agrees To Acquire PRF's DeepSolar/GridFeed AI Energy Platform For $1M 
PRF Technologies and Dotz Nano Sign Term Sheet for Strategic Collaboration to Expand AI-Driven Energy Optimization Offering 
12 Health Care Stocks Moving In Friday's After-Market Session 
PRF Technologies Reports Cash Of ~$11M As Of Sept. 30; Plans To Initiate Enrollment In Its U.S. Multi-Center Clinical Study Of OcuRing-K; Intendws To Estabish GridFeed vAs Standalone Subsidiary
Your note
Sign in to keep a note on PRFX — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| UBS Group AG | 0.74% | 6,496 | 28.97K | Sep 29, 2024 |
| Two Sigma Securities, LLC | 0.49% | 4,308 | 19.21K | Sep 29, 2024 |
| HRT Financial LP | 0.41% | 3,577 | 15.95K | Sep 29, 2024 |
| Osaic Holdings Inc | 0.02% | 192 | 856 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.01% | 80 | 356 | Sep 29, 2024 |